onc Videos

Videos

Videos

Strategies for Treating Frail and Transplant-Ineligible Patients With Multiple Myeloma

01/26/2023

Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.

Shaji Kumar, MD, provides...

01/26/2023

Oncology

Videos

Early MRD Clearance With Ibrutinib Plus Venetoclax Yields Sustained Clinical and MRD Responses in CLL

01/26/2023

Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.

Talha Munir, MD, discusses...

01/26/2023

Oncology

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA

Videos

Talazoparib for Patients With Somatic BRCA-Mutant Metastatic Breast Cancer

01/26/2023

At the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, discusses the ongoing phase 2 trial evaluating the efficacy of talazoparib for patients with BRCA-mutant, HER2-negative metastatic breast cancer.

At the 2022 San Antonio Breast...

01/26/2023

Oncology

Rachna Shroff, MD, University of Arizona Cancer Center

Videos

No Survival Benefit From Addition of Nab-paclitaxel to Gemcitabine-Cisplatin for Patients With Biliary Tract Cancers

01/26/2023

Rachna Shroff, MD, shares data from a phase 3 trial evaluating gemcitabine, cisplatin, and nab-paclitaxel for newly diagnosed, advanced biliary tract cancers.

Rachna Shroff, MD, shares data...

01/26/2023

Oncology

Cynthia Ma, MD, PhD, Washington University, St. Louis, MO

Videos

Selecting Neoadjuvant Therapy for HR-Positive Breast Cancer

01/26/2023

At the 2022 San Antonio Breast Cancer Symposium, Cynthia Ma, MD, PhD, discusses the neoadjuvant therapy options available for patients with HR-positive breast cancer.

At the 2022 San Antonio Breast...

01/26/2023

Oncology

Videos

AlloHSCT Outcomes From Younger Matched Unrelated Donors vs Older Sibling Donors for AML

01/25/2023

Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...

Muhammad Bilal Abid, MD,...

01/25/2023

Oncology

Ariella Hanker, PhD, UT Southwestern Medical Center, Dallas, TX

Videos

Biological Mechanisms of CDK4/6 Inhibitor Resistance

01/24/2023

At the 2022 San Antonio Breast Cancer Symposium, Ariella Hanker, PhD, discusses the biological mechanisms behind CDK4/6 inhibitor resistance and novel approaches being developed to overcome this resistance in patients with breast cancer.

At the 2022 San Antonio Breast...

01/24/2023

Oncology

Videos

Novel Therapeutic Strategies for TP53-Mutated Myeloid Malignancies: What is the Role of XPO1?

01/24/2023

Traci Kruer, PhD, discusses data from a phase 1/2 trial showing XPO1 overexpression is a mechanism of resistance to eprenetapopt and 5-azacitidine and can be therapeutically exploited to treat patients with TP53-mutated myeloid malignancies.

Traci Kruer, PhD, discusses data...

01/24/2023

Oncology

Videos

Novel Allogeneic Stem Cell Transplant Strategies to Mitigate Graft-Versus-Host Disease

01/24/2023

Caspian Oliai, MD, MS, provides insight into novel strategies in reducing GVHD, including orca-t cell therapy and post-transplant cyclophosphamide.

Caspian Oliai, MD, MS, provides...

01/24/2023

Oncology

Videos

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil for GVHD Prophylaxis in Reduced Intensity Conditioning

01/24/2023

Shernan G Holtan, MD, discusses findings from a phase 3 study on GVHD prophylaxis in reduced intensity conditioning, which she presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans, LA.

Shernan G Holtan, MD, discusses...

01/24/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology